Does the media refer more to PRAX or BIIB?

In the previous week, Biogen had 36 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 38 mentions for Biogen and 2 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.61 beat Biogen's score of 1.25 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Biogen 28 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALNY or PRAX?

In the previous week, Alnylam Pharmaceuticals had 24 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 26 mentions for Alnylam Pharmaceuticals and 2 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.61 beat Alnylam Pharmaceuticals' score of 1.14 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 20 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to PRAX or INSM?

In the previous week, Insmed had 5 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 7 mentions for Insmed and 2 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.61 beat Insmed's score of 0.90 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Insmed 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PRAX or ROIV?

In the previous week, Roivant Sciences had 19 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 21 mentions for Roivant Sciences and 2 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.61 beat Roivant Sciences' score of 0.61 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Roivant Sciences 8 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PRAX or MRNA?

In the previous week, Moderna had 75 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 77 mentions for Moderna and 2 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.61 beat Moderna's score of 0.42 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Moderna 33 Very Positive mention(s) 15 Positive mention(s) 7 Neutral mention(s) 10 Negative mention(s) 10 Very Negative mention(s) Neutral

Praxis Precision Medicines (PRAX) Competitors

$344.75 -23.10 (-6.28%)

As of 08/28/2026 04:00 PM Eastern

Compare

PRAX vs. BIIB, ALNY, INSM, ROIV, and MRNA

Should you buy Praxis Precision Medicines stock or one of its competitors? Praxis Precision Medicines's main competitors and comparable companies include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Insmed (INSM), Roivant Sciences (ROIV), and Moderna (MRNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Praxis Precision Medicines compare to Biogen?

Praxis Precision Medicines (NASDAQ:PRAX) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Praxis Precision Medicines has a beta of 2.78, indicating that its share price is 178% more volatile than the broader market. Comparatively, Biogen has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market.

Praxis Precision Medicines presently has a consensus price target of $585.95, indicating a potential upside of 69.96%. Biogen has a consensus price target of $227.79, indicating a potential upside of 4.25%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, equities research analysts clearly believe Praxis Precision Medicines is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	4 Strong Buy rating(s)	3.00
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

In the previous week, Biogen had 36 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 38 mentions for Biogen and 2 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.61 beat Biogen's score of 1.25 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Biogen	28 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,125.78	-$303.27M	-$12.93	N/A
Biogen	$10.03B	3.22	$1.29B	$5.65	38.67

Biogen has a net margin of 8.32% compared to Praxis Precision Medicines' net margin of 0.00%. Biogen's return on equity of 11.18% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
Biogen	8.32%	11.18%	6.88%

67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 3.0% of Praxis Precision Medicines shares are owned by company insiders. Comparatively, 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Biogen beats Praxis Precision Medicines on 10 of the 17 factors compared between the two stocks.

How does Praxis Precision Medicines compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Praxis Precision Medicines (NASDAQ:PRAX) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

In the previous week, Alnylam Pharmaceuticals had 24 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 26 mentions for Alnylam Pharmaceuticals and 2 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.61 beat Alnylam Pharmaceuticals' score of 1.14 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	20 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Alnylam Pharmaceuticals has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$4.80B	6.60	$313.75M	$5.38	44.07
Praxis Precision Medicines	$8.55M	1,125.78	-$303.27M	-$12.93	N/A

Alnylam Pharmaceuticals presently has a consensus target price of $386.14, indicating a potential upside of 62.86%. Praxis Precision Medicines has a consensus target price of $585.95, indicating a potential upside of 69.96%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Alnylam Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.92
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	4 Strong Buy rating(s)	3.00

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Alnylam Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.78, indicating that its stock price is 178% more volatile than the broader market.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Praxis Precision Medicines' net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Praxis Precision Medicines	N/A	-34.15%	-32.42%

Summary

Alnylam Pharmaceuticals beats Praxis Precision Medicines on 9 of the 16 factors compared between the two stocks.

How does Praxis Precision Medicines compare to Insmed?

Praxis Precision Medicines (NASDAQ:PRAX) and Insmed (NASDAQ:INSM) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Praxis Precision Medicines presently has a consensus target price of $585.95, suggesting a potential upside of 69.96%. Insmed has a consensus target price of $205.52, suggesting a potential upside of 73.38%. Given Insmed's higher possible upside, analysts plainly believe Insmed is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	4 Strong Buy rating(s)	3.00
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Praxis Precision Medicines has a beta of 2.78, indicating that its stock price is 178% more volatile than the broader market. Comparatively, Insmed has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market.

Praxis Precision Medicines has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Praxis Precision Medicines' return on equity of -34.15% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
Insmed	-76.94%	-123.94%	-44.30%

67.8% of Praxis Precision Medicines shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Insmed had 5 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 7 mentions for Insmed and 2 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.61 beat Insmed's score of 0.90 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Insmed	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Praxis Precision Medicines has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,125.78	-$303.27M	-$12.93	N/A
Insmed	$606.42M	42.69	-$1.28B	-$4.11	N/A

Summary

Praxis Precision Medicines beats Insmed on 11 of the 16 factors compared between the two stocks.

How does Praxis Precision Medicines compare to Roivant Sciences?

Praxis Precision Medicines (NASDAQ:PRAX) and Roivant Sciences (NASDAQ:ROIV) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Roivant Sciences has lower revenue, but higher earnings than Praxis Precision Medicines. Roivant Sciences is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,125.78	-$303.27M	-$12.93	N/A
Roivant Sciences	$8.26M	3,035.32	-$299.77M	-$0.53	N/A

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 8.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Praxis Precision Medicines has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

In the previous week, Roivant Sciences had 19 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 21 mentions for Roivant Sciences and 2 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.61 beat Roivant Sciences' score of 0.61 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Roivant Sciences	8 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Praxis Precision Medicines has a beta of 2.78, suggesting that its share price is 178% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Praxis Precision Medicines presently has a consensus price target of $585.95, indicating a potential upside of 69.96%. Roivant Sciences has a consensus price target of $35.14, indicating a potential upside of 1.23%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	4 Strong Buy rating(s)	3.00
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Summary

Praxis Precision Medicines beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

How does Praxis Precision Medicines compare to Moderna?

Praxis Precision Medicines (NASDAQ:PRAX) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Praxis Precision Medicines has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
Moderna	-141.43%	-28.30%	-19.39%

Praxis Precision Medicines has a beta of 2.78, suggesting that its stock price is 178% more volatile than the broader market. Comparatively, Moderna has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

In the previous week, Moderna had 75 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 77 mentions for Moderna and 2 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.61 beat Moderna's score of 0.42 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Moderna	33 Very Positive mention(s)	15 Positive mention(s)	7 Neutral mention(s)	10 Negative mention(s)	10 Very Negative mention(s)	Neutral

67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 3.0% of Praxis Precision Medicines shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Praxis Precision Medicines presently has a consensus price target of $585.95, suggesting a potential upside of 69.96%. Moderna has a consensus price target of $80.53, suggesting a potential downside of 41.64%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, equities analysts plainly believe Praxis Precision Medicines is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	4 Strong Buy rating(s)	3.00
Moderna	3 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.17

Praxis Precision Medicines has higher earnings, but lower revenue than Moderna. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,125.78	-$303.27M	-$12.93	N/A
Moderna	$1.94B	28.34	-$2.82B	-$7.99	N/A

Summary

Praxis Precision Medicines beats Moderna on 9 of the 17 factors compared between the two stocks.

Get Praxis Precision Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRAX vs. The Competition

Export

Metric	Praxis Precision Medicines	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.27B	$4.02B	$7.24B	$12.93B
Dividend Yield	N/A	3.60%	2.54%	10.96%
P/E Ratio	-26.66	11.56	271.50	25.38
Price / Sales	1,125.78	1,345.95	623.92	96.47
Price / Cash	N/A	110.59	79.29	54.21
Price / Book	7.18	16.50	12.95	6.14
Net Income	-$303.27M	-$22.76M	$3.46B	$347.93M
7 Day Performance	-8.27%	-0.23%	-0.11%	-0.78%
1 Month Performance	18.46%	11.93%	8.32%	5.60%
1 Year Performance	657.03%	55.61%	24.70%	15.64%

Praxis Precision Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRAX Praxis Precision Medicines	3.3372 of 5 stars	$344.75 -6.3%	$585.95 +70.0%	+649.6%	$10.27B	$8.55M	N/A	110
BIIB Biogen	3.5974 of 5 stars	$209.15 -0.3%	$227.07 +8.6%	+64.7%	$31.00B	$9.89B	37.02	7,500	Positive News Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.8791 of 5 stars	$224.60 -1.8%	$393.86 +75.4%	-47.6%	$30.60B	$3.71B	41.75	2,770	News Coverage Positive News Analyst Forecast Gap Down
INSM Insmed	3.3862 of 5 stars	$128.32 +3.7%	$205.52 +60.2%	-12.2%	$27.02B	$606.42M	N/A	1,664
ROIV Roivant Sciences	2.0147 of 5 stars	$36.24 +0.1%	$35.14 -3.0%	+190.7%	$26.15B	$8.26M	N/A	860	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRAX) was last updated on 8/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Praxis Precision Medicines (PRAX) Competitors

PRAX vs. BIIB, ALNY, INSM, ROIV, and MRNA

How does Praxis Precision Medicines compare to Biogen?

Summary

How does Praxis Precision Medicines compare to Alnylam Pharmaceuticals?

Summary

How does Praxis Precision Medicines compare to Insmed?

Summary

How does Praxis Precision Medicines compare to Roivant Sciences?

Summary

How does Praxis Precision Medicines compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX vs. The Competition

Praxis Precision Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Praxis Precision Medicines (PRAX) Competitors

PRAX vs. BIIB, ALNY, INSM, ROIV, and MRNA

How does Praxis Precision Medicines compare to Biogen?

Which has more volatility and risk, PRAX or BIIB?

Do analysts prefer PRAX or BIIB?

Does the media refer more to PRAX or BIIB?

Which has preferable valuation & earnings, PRAX or BIIB?

Is PRAX or BIIB more profitable?

Do insiders & institutionals have more ownership in PRAX or BIIB?

Summary

How does Praxis Precision Medicines compare to Alnylam Pharmaceuticals?

Does the media favor ALNY or PRAX?

Which has preferable valuation and earnings, ALNY or PRAX?

Do analysts rate ALNY or PRAX?

Do insiders and institutionals believe in ALNY or PRAX?

Which has more risk and volatility, ALNY or PRAX?

Is ALNY or PRAX more profitable?

Summary

How does Praxis Precision Medicines compare to Insmed?

Do analysts prefer PRAX or INSM?

Which has more risk and volatility, PRAX or INSM?

Is PRAX or INSM more profitable?

Do insiders & institutionals hold more shares of PRAX or INSM?

Does the media refer more to PRAX or INSM?

Which has higher earnings and valuation, PRAX or INSM?

Summary

How does Praxis Precision Medicines compare to Roivant Sciences?

Which has preferable valuation and earnings, PRAX or ROIV?

Do institutionals & insiders believe in PRAX or ROIV?

Is PRAX or ROIV more profitable?

Does the media refer more to PRAX or ROIV?

Which has more risk and volatility, PRAX or ROIV?

Do analysts recommend PRAX or ROIV?

Summary

How does Praxis Precision Medicines compare to Moderna?

Is PRAX or MRNA more profitable?

Which has more risk & volatility, PRAX or MRNA?

Does the media refer more to PRAX or MRNA?

Do institutionals and insiders hold more shares of PRAX or MRNA?

Do analysts recommend PRAX or MRNA?

Which has better valuation and earnings, PRAX or MRNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX vs. The Competition

Praxis Precision Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools